Willa D Brenowitz1, Lilah M Besser2, Walter A Kukull2, C Dirk Keene2, M Maria Glymour2, Kristine Yaffe2. 1. From the Departments of Psychiatry and Behavioral Sciences (W.D.B., K.Y.) and Neurology (K.Y.), Weill Institute for Neurosciences, and Department of Epidemiology & Biostatistics (M.M.G., K.Y.), University of California, San Francisco; Florida Atlantic University (L.M.B.), Institute for Human Health and Disease Intervention, School of Urban and Regional Planning, Boca Raton; National Alzheimer's Coordinating Center (W.A.K.), Department of Epidemiology, and Department of Pathology (C.D.K.), University of Washington, Seattle; and San Francisco VA Health Care System (K.Y.), CA. willa.brenowitz@ucsf.edu. 2. From the Departments of Psychiatry and Behavioral Sciences (W.D.B., K.Y.) and Neurology (K.Y.), Weill Institute for Neurosciences, and Department of Epidemiology & Biostatistics (M.M.G., K.Y.), University of California, San Francisco; Florida Atlantic University (L.M.B.), Institute for Human Health and Disease Intervention, School of Urban and Regional Planning, Boca Raton; National Alzheimer's Coordinating Center (W.A.K.), Department of Epidemiology, and Department of Pathology (C.D.K.), University of Washington, Seattle; and San Francisco VA Health Care System (K.Y.), CA.
Abstract
OBJECTIVE: To examine whether neuropathologic burden is associated with hearing impairment. METHODS: We studied 2,755 autopsied participants ≥55 years of age from the National Alzheimer's Coordinating Center database. Participants had at least 1 clinical evaluation at US National Institute on Aging-funded Alzheimer's Disease Center no more than 2 years before death. Patients were classified as hearing impaired by clinician report at baseline. Common dementia neuropathologies included Alzheimer disease pathologic change (Consortium to Establish a Registry for Alzheimer's Disease neuritic plaque density, neurofibrillary degeneration Braak stage), Lewy body disease, gross infarcts, and microinfarcts. Logistic regression models predicted impaired hearing with adjustment for age at death, sex, race, education, center, and follow-up time. Relative risks were calculated with the use of marginal standardization. RESULTS: Impaired hearing was common (32%). In participants who were cognitively normal at baseline (n = 580), impaired hearing was associated with higher Braak stage (relative risk [RR] 1.33 per 2-stage increase, 95% confidence interval [CI] 1.06-1.66) but not other pathologies. In participants with dementia (n = 2,175), impaired hearing was positively associated with microinfarcts (RR 1.18, 95% CI 1.00-1.39) and inversely associated with neuritic plaque density (RR 0.91 per score increase, 95% CI 0.85-0.99). Development of impaired hearing in those with cognitive impairment was associated with neocortical Lewy bodies (1.26, 95% CI 1.02-1.55). CONCLUSIONS: Impaired hearing, reported before the onset of cognitive impairment, was associated with increased neurofibrillary tangle burden. Impaired hearing in those with cognitive impairment was associated with microinfarcts and neocortical Lewy bodies but not typical Alzheimer disease pathologic change. Functional hearing problems may be a preclinical marker of neurofibrillary neurodegeneration, although replication is needed.
OBJECTIVE: To examine whether neuropathologic burden is associated with hearing impairment. METHODS: We studied 2,755 autopsied participants ≥55 years of age from the National Alzheimer's Coordinating Center database. Participants had at least 1 clinical evaluation at US National Institute on Aging-funded Alzheimer's Disease Center no more than 2 years before death. Patients were classified as hearing impaired by clinician report at baseline. Common dementia neuropathologies included Alzheimer disease pathologic change (Consortium to Establish a Registry for Alzheimer's Disease neuritic plaque density, neurofibrillary degeneration Braak stage), Lewy body disease, gross infarcts, and microinfarcts. Logistic regression models predicted impaired hearing with adjustment for age at death, sex, race, education, center, and follow-up time. Relative risks were calculated with the use of marginal standardization. RESULTS: Impaired hearing was common (32%). In participants who were cognitively normal at baseline (n = 580), impaired hearing was associated with higher Braak stage (relative risk [RR] 1.33 per 2-stage increase, 95% confidence interval [CI] 1.06-1.66) but not other pathologies. In participants with dementia (n = 2,175), impaired hearing was positively associated with microinfarcts (RR 1.18, 95% CI 1.00-1.39) and inversely associated with neuritic plaque density (RR 0.91 per score increase, 95% CI 0.85-0.99). Development of impaired hearing in those with cognitive impairment was associated with neocortical Lewy bodies (1.26, 95% CI 1.02-1.55). CONCLUSIONS: Impaired hearing, reported before the onset of cognitive impairment, was associated with increased neurofibrillary tangle burden. Impaired hearing in those with cognitive impairment was associated with microinfarcts and neocortical Lewy bodies but not typical Alzheimer disease pathologic change. Functional hearing problems may be a preclinical marker of neurofibrillary neurodegeneration, although replication is needed.
Authors: Clifford R Jack; David S Knopman; William J Jagust; Ronald C Petersen; Michael W Weiner; Paul S Aisen; Leslie M Shaw; Prashanthi Vemuri; Heather J Wiste; Stephen D Weigand; Timothy G Lesnick; Vernon S Pankratz; Michael C Donohue; John Q Trojanowski Journal: Lancet Neurol Date: 2013-02 Impact factor: 44.182
Authors: Mark A Eckert; Stefanie E Kuchinsky; Kenneth I Vaden; Stephanie L Cute; Maria V Spampinato; Judy R Dubno Journal: J Assoc Res Otolaryngol Date: 2013-03-20
Authors: Willa D Brenowitz; Rebecca A Hubbard; C Dirk Keene; Stephen E Hawes; W T Longstreth; Randy L Woltjer; Walter A Kukull Journal: Neurology Date: 2017-09-22 Impact factor: 9.910
Authors: John F Crary; John Q Trojanowski; Julie A Schneider; Jose F Abisambra; Erin L Abner; Irina Alafuzoff; Steven E Arnold; Johannes Attems; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Dennis W Dickson; Marla Gearing; Lea T Grinberg; Patrick R Hof; Bradley T Hyman; Kurt Jellinger; Gregory A Jicha; Gabor G Kovacs; David S Knopman; Julia Kofler; Walter A Kukull; Ian R Mackenzie; Eliezer Masliah; Ann McKee; Thomas J Montine; Melissa E Murray; Janna H Neltner; Ismael Santa-Maria; William W Seeley; Alberto Serrano-Pozo; Michael L Shelanski; Thor Stein; Masaki Takao; Dietmar R Thal; Jonathan B Toledo; Juan C Troncoso; Jean Paul Vonsattel; Charles L White; Thomas Wisniewski; Randall L Woltjer; Masahito Yamada; Peter T Nelson Journal: Acta Neuropathol Date: 2014-10-28 Impact factor: 17.088
Authors: Stephanie C Rigters; Daniel Bos; Mick Metselaar; Gennady V Roshchupkin; Robert J Baatenburg de Jong; M Arfan Ikram; Meike W Vernooij; André Goedegebure Journal: Front Aging Neurosci Date: 2017-01-20 Impact factor: 5.750
Authors: David R Moore; Mark Edmondson-Jones; Piers Dawes; Heather Fortnum; Abby McCormack; Robert H Pierzycki; Kevin J Munro Journal: PLoS One Date: 2014-09-17 Impact factor: 3.240
Authors: Taylor J Krivanek; Seth A Gale; Brittany M McFeeley; Casey M Nicastri; Kirk R Daffner Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.472
Authors: Alexandria L Irace; Brady Q Rippon; Adam M Brickman; José A Luchsinger; Justin S Golub Journal: Otol Neurotol Date: 2022-03-01 Impact factor: 2.311
Authors: Jeremy C S Johnson; Charles R Marshall; Rimona S Weil; Doris-Eva Bamiou; Chris J D Hardy; Jason D Warren Journal: Brain Date: 2021-03-03 Impact factor: 13.501